Chee Chung

Company: Arbor Biotechnologies

Job title: Vice President & Head of CNS Therapies

Seminars:

Pioneering Gene Editing for ALS: Advancing ABO-202 and a Pipeline of CNS-Directed Therapeutics 1:30 pm

Introducing Arbor’s gene editing platform and unique commitment to CNS and ALS Deep dive into ABO-202: AAV-delivered gene editing approach targeting STMN2 to restore protective neuronal function Preclinical data supporting progression of ABO-202 toward IND-enabling studies Future directions for Arbor’s gene editing programs in ALSRead more

day: Conference Day Two Track B PM